Temasek-led investor group in $250 million vaccine bet on Germany's BioNTech

FRANKFURT (Reuters) - Singapore's state investor Temasek and other investors are injecting $250 million into German biotech company BioNTech , which is developing an experimental vaccine against the coronavirus with pharmaceutical giant Pfizer .The investment, which BioNTech said was via a private placement, reflects heightened investor interest in the race to develop an agent that will stop the pandemic and sent shares in biotech firms such as Moderna and Novavax soaring this..